Antimuscarinics in men with lower urinary tract symptoms suggestive of bladder outlet obstruction due to benign prostatic hyperplasia

Current Opinion in Urology

Volumn 20, Issue 1, 2010, Pages 43-48

  Chapple, Christopher ^a  

^a SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antimuscarinics; Benign prostatic hyperplasia; Bladder outflow obstruction; Lower urinary tract symptoms; Overactive bladder

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; NAFTOPIDIL; OXYBUTYNIN; PLACEBO; PROPIVERINE; PROSTATE SPECIFIC ANTIGEN; SOLIFENACIN; TAMSULOSIN; TERAZOSIN; TOLTERODINE;

BLADDER NECK STENOSIS; CATHETERIZATION; CLINICAL ASSESSMENT; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INCIDENCE; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MICTURITION; MONOTHERAPY; NOCTURIA; OVERACTIVE BLADDER; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RATING SCALE; RESIDUAL VOLUME; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; URINE RETENTION; URODYNAMICS; XEROSTOMIA;

HUMANS; MALE; MUSCARINIC ANTAGONISTS; PROSTATIC HYPERPLASIA; PROSTATISM; URINARY BLADDER NECK OBSTRUCTION;

EID: 74549172019     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e3283330862     Document Type: Review

References (33)

1. Abrams P. New words for old: lower urinary tract symptoms for 'prostatism'. BMJ 1994; 308:929-930.
2. Turner-Warwick R, Whiteside CG, Worth PH, et al. A urodynamic view of the clinical problems associated with bladder neck dysfunction and its treatment by endoscopic incision and trans-trigonal posterior prostatectomy. Br J Urol 1973; 45:44-59.
3. Lepor H, Machi G. Comparison of AUA symptom index in unselected males and females between fifty-five and seventy-nine years of age. Urology 1993; 42:36-40.
4. Ameda K, Sullivan MP, Bae RJ, Yalla SV. Urodynamic characterization of nonobstructive voiding dysfunction in symptomatic elderly men. J Urol 1999; 162:142-146.
5. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-178. (Pubitemid 34195211)
6. Peters TJ, Donovan JL, Kay HE, et al. The International Continence Society 'Benign Prostatic Hyperplasia' Study: the botherosomeness of urinary symptoms. J Urol 1997; 157:885-889.
7. Sexton CC, Coyne KS, Kopp ZS, et al. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int 2009; 103 (Suppl 3): 12-23.
8. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20:327-336.
9. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87:760-766.
10. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50:1306-1314; discussion 14-15.
11. Rosier PF, de la Rosette JJ, Koldewijn EL, et al. Variability of pressure-flow analysis parameters in repeated cystometry in patients with benign prostatic hyperplasia. J Urol 1995; 153:1520-1525.
12. Hyman MJ, Groutz A, Blaivas JG. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol 2001; 166:550-552; discussion 3.
13. Oelke M, Baard J, Wijkstra H, et al. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol 2008; 54:419-426.
14. Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006; 175 (3 Pt 1):999-1004; discussion. (Pubitemid 43200054)
15. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006; 49:651-658.
16. Armitage J, Emberton M. The role of anticholinergic drugs in men with lower urinary tract symptoms. Curr Opin Urol 2008; 18:11-15.
17. Gallegos PJ, Frazee LA. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. Pharmacotherapy 2008; 28:356-365.
18. Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003; 169: 2253-2256.
19. Lee JY, Kim HW, Lee SJ, et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004; 94:817-820.
20. Lee KS, Choo MS, Kim DY, et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 2005; 174 (4 Pt 1):1334-1338.
21. Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006; 296:2319-2328.
22. Rovner ES, Kreder K, Sussman DO, et al. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol 2008; 180:1034-1041.
23. Kaplan SA, Roehrborn CG, Chancellor M, et al. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU Int 2008; 102:1133-1139.
24. Roehrborn CG, Kaplan SA, Jones JS, et al. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. Eur Urol 2009; 55:472-479.
25. Roehrborn CG, Kaplan SA, Kraus SR, et al. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology 2008; 72:1061-1067; discussion 7.
26. Yang Y, Zhao XF, Li HZ, et al. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. Chin Med J (Engl) 2007; 120:370-374.
27. Hofner K, Burkart M, Jacob G, Jonas U. Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed nonobstructive benign prostatic hyperplasia. World J Urol 2007; 25:627-633.
28. MacDiarmid SA, Peters KM, Chen A, et al. Efficacy and safety of extendedrelease oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2008; 83:1002-1010.
29. Chapple C, Herschorn S, Abrams P, et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alphablockers. Eur Urol 2009; 56:534-543.
30. Chapple CR, Herschorn S, Abrams P, et al. Tolterodine extended release improves overactive bladder symptoms in men treated with alpha-blockers irrespective of baseline serum prostate-specific antigen level [abstract]. Eur Urol Suppl 2009; 8:166.
31. Yokoyama T, Uematsu K, Watanabe T, et al. Naftopidil and propiverine hydrochloride for treatment ofmale lower urinary tract symptomssuggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scand J Urol Nephrol 2009; 43:307-314.
32. Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol 2009; 19:380-394.
33. Blake-James BT, Rashidian A, Ikeda Y, Emberton M. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int 2007; 99:85-96.